Literature DB >> 14722330

SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.

Claudine Serradeil-Le Gal1, Gérard Valette, Loïc Foulon, Guy Germain, Charles Advenier, Emmanuel Naline, Marc Bardou, Jean-Pierre Martinolle, Brigitte Pouzet, Danielle Raufaste, Corinne Garcia, Eléonore Double-Cazanave, Maxime Pauly, Marc Pascal, Alain Barbier, Bernard Scatton, Jean-Pierre Maffrand, Gérard Le Fur.   

Abstract

4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)benzamide, hydrochloride (SSR126768A), a new potent and selective, orally active oxytocin (OT) receptor antagonist was characterized in several biochemical and pharmacological models. In binding studies, SSR126768A showed nanomolar affinity for rat and human recombinant and native OT receptors (K(i) = 0.44 nM) and exhibited much lower affinity for V(1a), V(1b), and V(2) receptors. In addition, it did not interact with a large number of other receptors, enzymes, and ion channels (1 microM). In autoradiographic experiments performed on at-term human pregnant uterus sections, SSR126768A dose dependently displaced [I(125)]d(CH(2))(5)[Tyr(Me)(2), Thr(4), Orn(8) (125)I-Tyr-NH(2)(9)]VT in situ labeling to OT receptors highly expressed in these tissues. In functional studies, SSR126768A behaved as a full antagonist and potently antagonized OT-induced intracellular Ca(2+) increase (K(i) = 0.50 nM) and prostaglandin release (K(i) = 0.45 nM) in human uterine smooth muscle cells. In rat isolated myometrium, OT-induced uterine contractions were competitively antagonized by SSR126768A (pA(2) = 8.47). Similarly, in human pregnant myometrial strips, SSR126768A inhibited the contractile uterine response to OT. In conscious telemetrated rats, oral administration of SSR126768A (1-10 mg/kg) produced a competitive inhibition of the dose response to OT on uterine contractions up to 24 h at 3 mg/kg p.o.; no tachyphylaxis was observed after 4-day repeated treatment. Finally, SSR126768A (30 mg/kg p.o.) significantly delayed parturition in pregnant rats in labor similar to ritodrine (10 mg/kg p.o.). Thus, SSR126768A is a potent, highly selective, orally active OT receptor antagonist with a long duration of action. This molecule could find therapeutic application as a tocolytic agent for acute and chronic oral management of preterm labor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722330     DOI: 10.1124/jpet.103.061200

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.

Authors:  Maithé Corbani; Miguel Trueba; Stoytcho Stoev; Brigitte Murat; Julie Mion; Véra Boulay; Gilles Guillon; Maurice Manning
Journal:  J Med Chem       Date:  2011-03-23       Impact factor: 7.446

2.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  An overview of the oxytocin-oxytocin receptor signaling network.

Authors:  Oishi Chatterjee; Krutika Patil; Apeksha Sahu; Lathika Gopalakrishnan; Praseeda Mol; Jayshree Advani; Srabani Mukherjee; Rita Christopher; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2016-09-14       Impact factor: 5.782

Review 4.  REVIEW: Oxytocin: Crossing the bridge between basic science and pharmacotherapy.

Authors:  Cedric Viero; Izumi Shibuya; Naoki Kitamura; Alexei Verkhratsky; Hiroaki Fujihara; Akiko Katoh; Yoichi Ueta; Hans H Zingg; Alexandr Chvatal; Eva Sykova; Govindan Dayanithi
Journal:  CNS Neurosci Ther       Date:  2010-07-07       Impact factor: 5.243

Review 5.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

Review 6.  Oxytocin: the great facilitator of life.

Authors:  Heon-Jin Lee; Abbe H Macbeth; Jerome H Pagani; W Scott Young
Journal:  Prog Neurobiol       Date:  2009-04-10       Impact factor: 11.685

7.  Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.

Authors:  Rafik Marir; Anne Virsolvy; Kazimierz Wisniewski; Julie Mion; Dominique Haddou; Evelyne Galibert; Zahia Meraihi; Michel G Desarménien; Gilles Guillon
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

8.  Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment.

Authors:  Nada Choucair-Jaafar; Ipek Yalcin; Jean-Luc Rodeau; Elisabeth Waltisperger; Marie-José Freund-Mercier; Michel Barrot
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

9.  Inactivation of Socs3 in the hypothalamus enhances the hindbrain response to endogenous satiety signals via oxytocin signaling.

Authors:  Valéry Matarazzo; Fabienne Schaller; Emmanuelle Nédélec; Alexandre Benani; Luc Pénicaud; Françoise Muscatelli; Emmanuel Moyse; Sylvian Bauer
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

Review 10.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.